Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Infectious Diseases
Volume 2014 (2014), Article ID 573279, 3 pages
http://dx.doi.org/10.1155/2014/573279
Case Report

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

1Department of Pharmacy, Singapore General Hospital, Outram Road, Singapore 169608
2Department of Infectious Diseases, Singapore General Hospital, Outram Road, Singapore 169608
3Duke-NUS Emerging Infectious Diseases, 8 College Road, Singapore 169857

Received 18 February 2014; Accepted 26 May 2014; Published 3 June 2014

Academic Editor: Oguz R. Sipahi

Copyright © 2014 Yvonne Peijun Zhou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented.